Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition

PARP inhibitors (PARPi) are currently indicated for the treatment of ovarian, breast, pancreatic, and prostate cancers harboring mutations in the tumor suppressor genes BRCA1 or BRCA2. In the case of ovarian and prostate cancers, their classification as homologous recombination repair (HRR) deficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamal, Kunzah, Galbiati, Alessandro, Armenia, Joshua, Illuzzi, Giuditta, Hall, James, Bentouati, Sabrina, Barrell, Daniel, Ahdesmäki, Miika, O'Connor, Mark J., Leo, Elisabetta, Forment, Josep V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035383/
https://www.ncbi.nlm.nih.gov/pubmed/36969741
http://dx.doi.org/10.1158/2767-9764.CRC-22-0119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035383/
https://www.ncbi.nlm.nih.gov/pubmed/36969741
http://dx.doi.org/10.1158/2767-9764.CRC-22-0119

Ejemplares similares